Daniel So, MD
Endocrinology, Diabetes & Metabolism · Arlington Heights, ILNPI 1023167004
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $243,472 of the $283,075 with a category attached, or 86.0%. 60 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 29.8% of the total. Among endocrinology, diabetes & metabolism clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,604 payments — averaging $176.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$84K
- Lilly USA, LLC$72K
- Boehringer Ingelheim$70K
- AstraZeneca$20K
- AbbVie$17K
- Dexcom, Inc.$3K
- plus $17K from 54 others
Across 1 payment — averaging $375.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche Diabetes Care, Inc.$375
What the payments were for
- Consulting fees$2,9251%
- Speaking & faculty fees$243,47286%
- Travel & lodging$2,5891%
- Food & beverage$33,44012%
- Education$4900%
- Other$1600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$120,564
- SOLIQUA 100/33$51,300
- TOUJEO$31,038
- FARXIGA$18,015
- Synthroid$16,181
- Rayaldee$490
- TZIELD$408
- iLet Bionic Pancreas$395
- Korlym$378
- NEXLIZET$245
- NEXLETOL$245
- EVENITY$234
- MOUNJARO$231
- TEPEZZA$217
- DEXCOM G6 TRANSMITTER$174
- MYCAPSSA$150
- MINIMED 770G$147
- FreeStyle Libre 2$146
- CRENESSITY$134
- Vascepa$121
How this compares
$283,075 in reported general payments places this provider in the 95th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
See all endocrinology, diabetes & metabolism providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 549 | $750,892 |
| OzempicSemaglutide | 367 | $629,209 |
| FarxigaDapagliflozin Propanediol | 256 | $316,283 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 117 | $189,643 |
| MounjaroTirzepatide | 97 | $188,349 |
| TrulicityDulaglutide | 81 | $153,068 |
| RybelsusSemaglutide | 86 | $152,353 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 123 | $102,832 |
| Humalog Kwikpen U-100Insulin Lispro | 222 | $95,999 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 56 | $94,851 |
| Tresiba Flextouch U-100Insulin Degludec | 116 | $86,908 |
| JanuviaSitagliptin Phosphate | 65 | $81,388 |
| Novolog FlexpenInsulin Aspart | 188 | $71,916 |
| Bydureon BciseExenatide Microspheres | 47 | $71,630 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 117 | $67,533 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Tradjenta | $69,768 | $820,915593 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $1,565 | $796,154493 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $71,562 | $362,274255 claims |
| AstraZenecaFarxiga | $19,518 | $316,283256 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $84,362 | $201,030182 claims |
| MerckJanuvia | $409 | $81,38865 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $857 | $17,2181,320 claims |
| Johnson & JohnsonInvokana | $324 | $14,94911 claims |
| AbbVieSynthroid | $17,120 | $12,604179 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
Other endocrinology, diabetes & metabolism in Arlington Heights
- Mario ChanArlington Heights$32K
- Luis SorucoArlington Heights$27K
- Zubair IlyasArlington Heights$16K
- Wahid KassarChicago$884K
- Anthony PickLake Forest$665K
- Babak PazookiJoliet$582K
- Ammar BayrakdarEvergreen Park$517K
- George BakrisChicago$403K
- Terrence SwadeLombard$369K
- Wenyu HuangChicago$341K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.